
Schoolgirls in Scotland became the first in the UK to get immunised against cervical cancer on Monday.
Pupils aged 12 and 13 in several areas are being offered the vaccine from this week, as part of a nationwide programme announced last October.
Advertisement
The programme will eventually see all girls in Britain up to the age of 18 receive the jab -- although it is not compulsory.
Scotland is the first to start the campaign as schools there started the autumn term earlier than elsewhere in Britain.
The Cervarix vaccination works by targeting the human papillomavirus, which causes around 70 percent of cases of cervical cancer.
More than 1,000 women in the UK die every year from cervical cancer.
The vaccine costs around 300 pounds and will be offered in three doses over a six-month period.
Jeanette Cairns, a school nurse co-ordinator with NHS Tayside, one of the first areas to carry out vaccinations, said: "Girls should not feel nervous about coming for the vaccination.
"It is just a small injection into the arm that will protect them for many years against cervical cancer."
Source: AFP
SRM
The Cervarix vaccination works by targeting the human papillomavirus, which causes around 70 percent of cases of cervical cancer.
Advertisement
More than 1,000 women in the UK die every year from cervical cancer.
The vaccine costs around 300 pounds and will be offered in three doses over a six-month period.
Jeanette Cairns, a school nurse co-ordinator with NHS Tayside, one of the first areas to carry out vaccinations, said: "Girls should not feel nervous about coming for the vaccination.
"It is just a small injection into the arm that will protect them for many years against cervical cancer."
Source: AFP
SRM
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Cancer News

The combination of the personalized cancer vaccine with ACT led to ovarian cancer control in few patients within a span of three months, stated study results.

Uncovering key kinases in tumor growth and invasion is crucial for improving targeted therapies in advanced-stage colorectal cancer.

The study findings validate metal-enhanced photo-oxidation for future metal-based anticancer drugs.

Mutations in 11 genes are linked to aggressive forms of prostate cancer, which may present novel therapeutic and therapy options.

Improved oral health, as indicated by the count of natural teeth and dental appointments preceding the diagnosis, correlated with enhanced head and neck cancer survival rates.